493 related articles for article (PubMed ID: 37480633)
1. Value contribution of cenobamate for the treatment of Focal-Onset Seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through reflective Multi-Criteria Decision Analysis (MCDA).
Falip M; López González FJ; Martín-Herranz I; Merino-Bohórquez V; Montoya J; Rey Gómez-Serranillos I; Rodriguez Uranga JJ; Ruiz E; Sancho-López A; Trillo Mata JL; Antoni Vallès J; Álvarez-Barón E; Sabaniego J; Subías-Labazuy S; Gil A
Epilepsy Behav; 2023 Aug; 145():109350. PubMed ID: 37480633
[TBL] [Abstract][Full Text] [Related]
2. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).
Villanueva V; Carreño M; Gil-Nagel A; Serrano-Castro PJ; Serratosa JM; Toledo M; Álvarez-Barón E; Gil A; Subías-Labazuy S
Epilepsy Behav; 2021 Sep; 122():108222. PubMed ID: 34371462
[TBL] [Abstract][Full Text] [Related]
3. Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain.
Villanueva V; Serratosa JM; Toledo M; Ángel Calleja M; Navarro A; Sabaniego J; Pérez-Domper P; Álvarez-Barón E; Subías S; Gil A
Epilepsy Behav; 2023 Feb; 139():109054. PubMed ID: 36603345
[TBL] [Abstract][Full Text] [Related]
4. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
[TBL] [Abstract][Full Text] [Related]
5. Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.
Ángel Calleja M; Navarro A; Serratosa JM; Toledo M; Villanueva V; Subías Labazuy S; Gil A
Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1127-1136. PubMed ID: 35904256
[TBL] [Abstract][Full Text] [Related]
6. Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study.
Serrano-Castro PJ; Ramírez-García T; Cabezudo-Garcia P; Garcia-Martin G; De La Parra J
CNS Drugs; 2024 Feb; 38(2):141-151. PubMed ID: 38265735
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A "real-world" retrospective study.
Peña-Ceballos J; Moloney PB; Munteanu T; Doyle M; Colleran N; Liggan B; Breen A; Murphy S; El-Naggar H; Widdess-Walsh P; Delanty N
Epilepsia; 2023 May; 64(5):1225-1235. PubMed ID: 36790345
[TBL] [Abstract][Full Text] [Related]
8. A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: A systematic review and network meta-analysis.
Mulheron S; Leahy TP; McStravick M; Doran R; Delanty N
Seizure; 2024 May; 118():80-90. PubMed ID: 38643679
[TBL] [Abstract][Full Text] [Related]
9. An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug resistant epilepsy in the United States.
Raspin C; Faught E; Armand J; Barion F; Pollit V; Murphy J; Danielson V
J Med Econ; 2023; 26(1):189-199. PubMed ID: 36691763
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of cenobamate for focal seizures in people with drug-resistant epilepsy.
Laskier V; Agyei-Kyeremateng KK; Eddy AE; Patel D; Mulheron S; James S; Thomas RH; Sander JW
Epilepsia; 2023 Apr; 64(4):843-856. PubMed ID: 36625423
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study.
Rosenfeld WE; Nisman A; Ferrari L
Epilepsy Res; 2021 May; 172():106592. PubMed ID: 33662894
[TBL] [Abstract][Full Text] [Related]
12. Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures.
Privitera M; Richy FF; Schabert VF
Epilepsy Behav; 2022 Jan; 126():108429. PubMed ID: 34864380
[TBL] [Abstract][Full Text] [Related]
13. Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).
Jiménez A; Ais A; Beaudet A; Gil A
Orphanet J Rare Dis; 2018 Dec; 13(1):220. PubMed ID: 30526673
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive cenobamate for the treatment of focal onset seizures in adults with epilepsy: a critical review.
Wheless JW
Expert Rev Neurother; 2020 Nov; 20(11):1085-1098. PubMed ID: 33031714
[TBL] [Abstract][Full Text] [Related]
15. Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures.
Carreño M; Gil-Nagel A; Serratosa JM; Toledo M; Rodriguez-Uranga JJ; Villanueva V
Epilepsia Open; 2024 Apr; ():. PubMed ID: 38573131
[TBL] [Abstract][Full Text] [Related]
16. Real-world analysis of retention on cenobamate in patients with epilepsy in the United States.
Stern S; Weingarten M; Mandapati S; Ferrari L; Wade CT
Epilepsy Res; 2023 Nov; 197():107207. PubMed ID: 37741165
[TBL] [Abstract][Full Text] [Related]
17. Failure to use new breakthrough treatments for epilepsy.
Klein P; Krauss GL; Steinhoff BJ; Devinsky O; Sperling MR
Epilepsia; 2023 Jun; 64(6):1458-1465. PubMed ID: 36855241
[TBL] [Abstract][Full Text] [Related]
18. Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis.
Lattanzi S; Trinka E; Zaccara G; Striano P; Russo E; Del Giovane C; Silvestrini M; Brigo F
Drugs; 2022 Feb; 82(2):199-218. PubMed ID: 35061214
[TBL] [Abstract][Full Text] [Related]
19. An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England.
Raspin C; Shankar R; Barion F; Pollit V; Murphy J; Sawyer L; Danielson V
J Med Econ; 2021; 24(1):1037-1051. PubMed ID: 34348576
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.
Krauss GL; Klein P; Brandt C; Lee SK; Milanov I; Milovanovic M; Steinhoff BJ; Kamin M
Lancet Neurol; 2020 Jan; 19(1):38-48. PubMed ID: 31734103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
